AI-Powered Advocate 'Ari' to Support Rare Disease Families, Starting with Angelman Syndrome Community
The inherited retinal disease (IRD) community often faces significant challenges in navigating complex healthcare systems, coordinating care, and staying informed about the latest research and clinical trials. A recent development in the broader rare disease landscape offers a glimpse into how artificial intelligence (AI) could soon alleviate some of these burdens. Fierce Healthcare reports that a rare disease foundation has partnered with Citizen Health to integrate an AI agent, named Ari, into the daily care of affected families. This initiative, while currently focused on another rare condition, highlights a promising trend that could eventually benefit individuals and families living with IRDs.
What is Ari and How Will It Help?
Ari is an artificial intelligence-powered advocate designed specifically for rare disease communities. Its purpose is to assist patients and caregivers in managing the often overwhelming administrative tasks associated with complex conditions. Citizen Health, the developer behind Ari, describes it as a proactive advocate that can interpret medical records, track symptoms, manage appointments, and help connect families to the next steps in their health journey. The platform aims to aggregate medical records, aid in care coordination, and convert consented patient data into regulatory-grade real-world evidence to accelerate medical research and drug development.
The initial rollout of Ari is in partnership with the Angelman Syndrome Foundation (ASF), making it one of the first foundations to directly provide this AI tool to its families. Angelman syndrome is a rare neurodevelopmental disorder, and families managing it often deal with challenges like seizures and a growing number of investigational therapies. Amanda Moore, CEO of the Angelman Syndrome Foundation, stated that the partnership aligns with ASF's mission to make the journey easier for families facing a difficult diagnosis. ASF families will gain access to Ari at the 2026 ASF Family Conference, with a phased rollout beginning in the United States and expanding globally.
Broader Implications for Rare Disease Communities
Citizen Health was launched in late 2023 with the goal of helping patients and families navigate and manage rare and complex conditions. The company's platform is free for patients and families, generating revenue by licensing de-identified, aggregated real-world evidence and datasets to pharmaceutical companies. Citizen Health's co-founder, Nasha Fitter, was inspired by her own daughter's diagnosis with a rare disease, FOXG1 syndrome, and recognized the significant gap in technology support for rare disease communities. She noted that